Knight Therapeutics (TSE:GUD)
TSX:GUD
Total Valuation
Knight Therapeutics has a market cap or net worth of C$740.16M. The enterprise value is C$751.10M.
Market CapC$740.16M
Enterprise ValueC$751.10M
Share Statistics
Knight Therapeutics has 98,034,744 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,034,744
Owned by Insiders30.61%
Owned by Institutions0.09%
Financial Efficiency
Knight Therapeutics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.20%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.20%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee604.14K
Profits Per Employee-7.21K
Employee Count745
Asset Turnover0.43
Inventory Turnover2.20
Valuation Ratios
The current PE Ratio of Knight Therapeutics is ―. Knight Therapeutics’s PEG ratio is 0.50.
PE Ratio―
PS Ratio1.34
PB Ratio0.79
Price to Fair Value0.79
Price to FCF8.81
Price to Operating Cash Flow10.89
PEG Ratio0.50
Income Statement
In the last 12 months, Knight Therapeutics had revenue of 450.09M and earned -5.37M in profits. Earnings per share was -0.05.
Revenue450.09M
Gross Profit150.74M
Operating Income-2.20M
Pretax Income-6.70M
Net Income-5.37M
EBITDA54.37M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was 68.78M and capital expenditures -29.74M, giving a free cash flow of 39.04M billion.
Operating Cash Flow68.78M
Free Cash Flow39.04M
Free Cash Flow per Share0.40
Dividends & Yields
Knight Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.36
52-Week Price Change30.85%
50-Day Moving Average6.50
200-Day Moving Average6.17
Relative Strength Index (RSI)72.03
Average Volume (3m)48.52K
Important Dates
Knight Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Knight Therapeutics as a current ratio of 2.39, with Debt / Equity ratio of 10.15%
Current Ratio2.39
Quick Ratio1.57
Debt to Market Cap0.12
Net Debt to EBITDA0.03
Interest Coverage Ratio-0.21
Taxes
In the past 12 months, Knight Therapeutics has paid -1.33M in taxes.
Income Tax-1.33M
Effective Tax Rate0.20
Enterprise Valuation
Knight Therapeutics EV to EBITDA ratio is 11.11, with an EV/FCF ratio of 8.83.
EV to Sales1.34
EV to EBITDA11.11
EV to Free Cash Flow8.83
EV to Operating Cash Flow8.59
Balance Sheet
Knight Therapeutics has C$95.28M in cash and marketable securities with C$77.91M in debt, giving a net cash position of C$17.37M billion.
Cash & Marketable SecuritiesC$95.28M
Total DebtC$77.91M
Net CashC$17.37M
Net Cash Per ShareC$0.18
Tangible Book Value Per ShareC$2.99
Margins
Gross margin is 37.98%, with operating margin of -0.49%, and net profit margin of -1.19%.
Gross Margin37.98%
Operating Margin-0.49%
Pretax Margin-1.49%
Net Profit Margin-1.19%
EBITDA Margin12.08%
EBIT Margin-0.49%
Analyst Forecast
The average price target for Knight Therapeutics is C$8.99, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetC$8.99
Price Target Upside19.07% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast18.70%
EPS Growth Forecast88.31%